Frequency and risk factors for retinopathy associated with pegylated interferon .ALPHA.2b and ribavirin combination therapy in patients with chronic hepatitis C

DOI Web Site Web Site 8 References
  • Okuse Chiaki
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Ikeda Hiroki
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Nagase Yoshihiko
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Yamada Norie
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Okamoto Masaru
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Kobayashi Minoru
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Takahashi Hideaki
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Katakura Yoshiki
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Matsunaga Kotarou
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Matsumoto Nobuyuki
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Yotsuyanagi Hiroshi
    Department of Infectious Disease, Internal Medicine, University of Tokyo
  • Koike Kazuhiko
    Department of Infectious Disease, Internal Medicine, University of Tokyo
  • Iino Shiro
    Center of Liver Disease, Kiyokawa Hospital
  • Suzuki Michihiro
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Itoh Fumio
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine

Bibliographic Information

Other Title
  • Ｃ型慢性肝炎に対するペグインターフェロン・リバビリン併用療法におけるインターフェロン網膜症の検討
  • Cガタ マンセイ カンエン ニ タイスル ペグインターフェロン リバビリン ヘイヨウ リョウホウ ニ オケル インターフェロン モウマクショウ ノ ケントウ
  • Frequency and risk factors for retinopathy associated with pegylated interferon α2b and ribavirin combination therapy in patients with chronic hepatitis C

Search this article

Description

We investigated the frequency and risk factors for interferon associated retinopathy in 39 patients with chronic hepatitis C who were treated by pegylated interferon α2b and ribavirin combination therapy for 48 weeks. Optic fundi were examined before, 2, 4, 8, 24, and 48 weeks after the start and 24 weeks after the end of therapy. Nine patients (23.1%) developed retinopathy. No patient complained of visual disturbance. Retinopathy disappeared in all patients after the end of therapy. Hypertension was found to be the factor for predicting retinopathy by multiple logistic regression analysis. It is suggested that patients who are being treated for pegylated interferon and ribavirin combination therapy, particularly those with hypertension, should undergo periodic examination of the optic fundi.<br>

Journal

  • Kanzo

    Kanzo 49 (11), 520-523, 2008

    The Japan Society of Hepatology

References(8)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top